Atrial Fibrillation Market Report to 2023

AF is one of the most common cardiovascular diseases among the elderly, worldwide. Although AF affects people of all ages, the condition is rare in individuals younger than 40 years of age. The risk for AF increases rapidly with age and is more common in men than women. Globally, the prevalence of AF varies widely, depending on the country and the study, ranging from 0.1-1.6% in Asia (0.1% in India, 1.6% in Japan), 0.95-3.9% in North America (0.95% in the US, 3.9% in Canada), 1.28-2.1% in Europe (1.28% in the UK, 2.1% in Germany), and 4.0% in Australia.

GlobalData’s epidemiological forecast for the diagnosed prevalent cases of AF in the 8MM is supported by epidemiologic data from country-specific studies that are nationally representative of the entire population in these markets. This analysis included the most recently published nationally-representative studies in the 8MM, which provided the diagnosed prevalence of AF using uniform diagnostic criteria based on EKG tests, which facilitated a meaningful comparison of the forecast for the diagnosed prevalent cases of AF in the 8MM.

Complete Report is available http://www.rnrmarketresearch.com/epicast-report-atrial-fibrillation-epidemiology-forecast-to-2023-market-report.html .

Scope:

• The Atrial Fibrillation (AF) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AF segmented by sex, age (in five-year age groups, beginning at 40 years and ending at =85 years), and clinical subtypes (paroxysmal, persistent, and permanent AF) in these markets.
• The AF epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=170326 . (This is a premium report priced at US$3995 for a single user License.)

Reasons to Buy:

• Develop business strategies by understanding the trends shaping and driving the global AF market.
• Quantify patient populations in the global AF market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AF therapeutics in each of the markets covered.

Table of Contents:

1 Table of Contents 4

2 Introduction 7

3 Epidemiology 9

4 Appendix 40

List of Tables:

Table 1: Clinical Subtypes of AF 9
Table 2: Risk Factors and Comorbidities for AF 11
Table 3: Diagnosed Prevalence (%) of AF in the 6MM,* as Reported in Epidemiological Studies 12
Table 4: Total Prevalence (%) of AF in the 7MM,* as Reported in Epidemiological Studies 13
Table 5: 8MM, Sources of Prevalence Data Used to Forecast the Diagnosed Prevalent Cases of AF 15
Table 6: 8MM, Sources of AF Subtype Data Used to Forecast the Diagnosed Prevalent Cases of AF by Subtypes 16

Explore more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.